Latest in Advocacy

  • Insulin Affordability Matters: Advocating to Make Insulin More Affordable for All

    November 14, 2019

    More than 1.25 million Americans live with type 1 diabetes (T1D), and this number continues to grow. They need insulin several times...

  • New JDRF-Funded Study finds Lifetime T1D Management Costs a Collective $813 Billion

    February 24, 2020

    Cost for each diagnosed American is nearly $500,000.

  • FDA Approves Xeris Pharmaceuticals’ Glucagon to Treat Severe Hypoglycemia

    September 11, 2019

    “The approval of the GVOKE HypoPenTM is an important step forward for people with diabetes. Severe hypoglycemia is a terrifying and dangerous...

  • Testimony of Dr. Aaron Kowalski, Chief Mission Officer, JDRF House Energy & Commerce Committee Oversight And Investigations Subcommittee

    April 2, 2019

    ‘PRICED OUT OF A LIFESAVING DRUG: THE HUMAN IMPACT OF RISING INSULIN COSTS’ Chairwoman DeGette, Ranking Member Guthrie, Chairman Pallone, Ranking Member...

  • In a Step Backward, UnitedHealthcare Changes Policy to Limit Insulin Pumps for Children

    February 4, 2019

    On February 1, 2019, UnitedHealthcare (UHC) announced a significant change to its insulin pump coverage policy, as it will no longer cover...

  • Congress, Protect Coverage for Pre-Existing Conditions for People with T1D

    December 15, 2018

    In the past year, tens of thousands of JDRF advocates have supported the #Coverage2Control campaign and our push for affordability, choice and...

  • Recognize. Recharge. Repeat. Appreciating Our Shared Success.

    July 30, 2018

    Whenever the JDRF community gathers, one thing remains clear: our singular focus on the fight to end type 1 diabetes (T1D) has...